Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Scientific Reports|March 23, 2017
Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast CancerMinghao Wang, Lingmi Hou, Maoshan Chen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 30, 2016
FAT4 functions as a tumor suppressor in triple-negative breast cancerLingmi Hou, Maoshan Chen, Xiaobo Zhao, et al.
BMC Medical Imaging|September 2, 2022
A comparative analysis of diagnostic values of high-frequency ultrasound and fiberoptic ductoscopy for pathologic nipple dischargeHongmei Yuan, Xuemei Tang, Xurong Mou, et al.
The Journal of Surgical Research|May 1, 2022
What Is the Optimal Strategy for Drain Removal After Mastectomy and Axillary Surgery in Breast Cancer Patients? A Multicenter, Three-Arm Randomized Clinical TrialNan Wen, Chibin Ouyang, Xiaoxia Hu, et al.
Discover Oncology|May 12, 2025
Global trends and research hotspots in autophagy and tumor drug resistance: a bibliometric analysisLong Zhao, Jiao Zeng, Junfeng Wen, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 21, 2016
Differential effects of bisphenol A diglicydyl ether on bone quality and marrow adiposity in ovary-intact and ovariectomized ratsGuanwu Li, Zheng Xu, Lingmi Hou, et al.
Gland Surgery|July 16, 2021
The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER databaseLingmi Hou, Mengxue Qiu, Maoshan Chen, et al.
Materials Today. Bio|September 19, 2025
A selective RCC1 inhibitor loaded in membrane-coated DNA nanocage for targeted suppression of TNBC progressionYunbo Luo, Yali Wang, Xiaohan Su, et al.
Basic & Clinical Pharmacology & Toxicology|May 22, 2018
IL-6 Triggers the Migration and Invasion of Oestrogen Receptor-Negative Breast Cancer Cells via Regulation of Hippo PathwaysLingmi Hou, Shaoli Xie, Guanwu Li, et al.
Scientific Reports|January 3, 2024
ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancerYunbo Luo, Qingyun Li, Jiang Fang, et al.
Pageof 6